Gufic BioScience

Part of MojoOne Strategy

Market Cap: Small Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE742B01025
NSEID: GUFICBIO
BSEID: 509079

INR

322.15

8.85 (2.82%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 26.3 k

Click here to access the older version

Score

Part of MojoOne Strategy

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Divi's Lab.

Cipla

Panacea Biotec

Sun Pharma.Inds.

Torrent Pharma

Morepen Labs.

Guj. Themis Bio.

Aarti Drugs

Gufic BioScience

Dishman Carbogen

Mankind Pharma

Why is Gufic BioSciences Ltd ?

Negative results in Dec 24

OPERATING PROFIT TO INTEREST(Q) Lowest at 6.91 times
INTEREST(HY) At Rs 10.09 cr has Grown at 22.01%
PBDIT(Q) Lowest at Rs 33.92 cr.

Stock is technically in a Bearish range

The technical trend has deteriorated from Sideways on 21-Mar-25 and has generated -4.99% returns since then
Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST

With ROCE of 15.3, it has a Expensive valuation with a 4.1 Enterprise value to Capital Employed

The stock is trading at a fair value compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 4.66%, its profits have fallen by -2.6%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Gufic BioScience for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Gufic BioScience

3.84%

0.10

45.16%

SENSEX

0.45%

0.03

14.48%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

17.10%

EBIT Growth (5y)

26.12%

EBIT to Interest (avg)

11.14

Debt to EBITDA (avg)

1.99

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

2.18

Tax Ratio

25.97%

Dividend Payout Ratio

1.16%

Pledged Shares

Institutional Holding

3.29%

ROCE (avg)

27.06%

ROE (avg)

23.19%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.90

EV to EBIT

27.56

EV to EBITDA

24.17

EV to Capital Employed

4.12

EV to Sales

4.25

PEG Ratio

Dividend Yield

0.03%

ROCE (Latest)

15.31%

ROE (Latest)

15.40%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

NET SALES(Q)

Highest at Rs 207.79 cr

-14What is not working for the Company

OPERATING PROFIT TO INTEREST(Q)

Lowest at 6.91 times

INTEREST(HY)

At Rs 10.09 cr has Grown at 22.01%

PBDIT(Q)

Lowest at Rs 33.92 cr.

OPERATING PROFIT TO NET SALES (Q)

Lowest at 16.32%

PBT LESS OI(Q)

Lowest at Rs 24.40 cr.

PAT(Q)

At Rs 19.31 cr has Fallen at -9.1% (vs previous 4Q average

EPS(Q)

Lowest at Rs 1.93

Loading Valuation Snapshot...

Here's what is working for Gufic BioScience

Net Sales - Quarterly

Highest at Rs 207.79 cr

in the last five quarters

MOJO Watch

Near term sales trend is positive

Net Sales (Rs Cr)

Here's what is not working for Gufic BioScience

Operating Profit to Interest - Quarterly

Lowest at 6.91 times and Fallen

each quarter in the last five quarters

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 24.40 cr has Fallen at -12.4% (vs previous 4Q average)

over average PBT of the previous four quarters of Rs 27.84 Cr

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Interest - Half Yearly

At Rs 10.09 cr has Grown at 22.01%

over previous Half yearly period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Operating Profit (PBDIT) - Quarterly

Lowest at Rs 33.92 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly

Lowest at 16.32%

in the last five quarters

MOJO Watch

Company's efficiency has deteriorated

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly

Lowest at Rs 24.40 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 19.31 cr has Fallen at -9.1% (vs previous 4Q average)

over average PAT of the previous four quarters of Rs 21.24 Cr

MOJO Watch

Near term PAT trend is negative

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly

Lowest at Rs 1.93

in the last five quarters

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (Rs)

Non Operating Income - Quarterly

Highest at Rs 1.86 cr

in the last five quarters

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating Income